Pos1508-HPR Implementation Perspectives of Using a Digital Patient Education Programme in Clinical Practice

Background: The integration of telehealth interventions into clinical practice is frequently delayed, hindering the full adoption 1. Previously, we developed a digital patient education programme for self-management in rheumatoid arthritis (RA) 2. The programme design considered crucial factors to ensure the likelihood of success in clinical practice. Still, there is a need for a thorough and systematic evaluation of implementation perspectives. Objectives: To explore perspectives of implementation in using a digital patient education programme in clinical practice. Methods: The non-adoption, abandonment, scale-up, spread and sustainability (NASSS) framework 3 was used to evaluate the facilitators and challenges of implementing the digital patient education programme. We included a primary data set consisting of qualitative focus group discussions involving study nurses, rheumatologists, and leaders from rheumatology departments (n=10), who had participated in a randomised controlled trial examining the effectiveness of the digital PE programme. Data analysis was guided by a deductive content analysis approach. Further we included secondary data from earlier studies, comprising the programme development process, the effectiveness study, and a qualitative study exploring patients' perspectives of the programme. Results: Facilitators and challenges of importance to implementation of digital patient education were identified: Conclusion: The design and ease of use of the technology, the programme's effectiveness, its availability, and the potential to release healthcare resources may encourage the implementation of digital patient education. Challenges associated with implementing this mode of care pertains to the illness and the patient population, user adoption of the technology, and the organization of patient education. REFERENCES: 1 de Thurah A, et al. Ann Rheum Dis. 2022. 2 Knudsen LR, et al. PEC Innovation. 2022. 3 Greenhalgh T, et al. J Med Internet Res. 2017. Acknowledgements: NIL. Disclosure of Interests: Line Raunsbæk Knudsen Phizer, Novartis, Eli Lilly, Kirsten Lomborg: None declared, Ellen-Margrethe Hauge Novo Nordic, Novartis, AbbVie, Sanofi, MSD, UCB, Novo Nordic Foundation, Galapagos, AbbVie, Roche, Novartis, Annette de Thurah: None declared.